(603896)"Zhejiang Shouxiangu Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603896 · · 13 pages · Chinese
Summary by 6ix AI
The report indicates significant declines in key financial metrics, including total revenue and net profit compared to the previous year. The company attributes these declines to economic slowdown and weak consumer demand, impacting its revenue and profit margins. The report also includes a summary of the company's assets and liabilities as of the end of the reporting period.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Zhejiang Shouxiangu Pharmaceutical Holding Co. Ltd. on 6ix
Earlier from Zhejiang Shouxiangu Pharmaceutical
- (603896)"Zhejiang Shouxiangu Pharmaceutical Co., Ltd."Indicative Announcement on "Shouxiangu 22 Convertible Bonds" Expected to Meet the Conditions for Revising the Conversion Price Downward
- (603896)"Zhejiang Shouxiangu Pharmaceutical Co., Ltd."Announcement on Release of Certain Guarantees for Wholly-owned Subsidiary
- (603896)"Zhejiang Shouxiangu Pharmaceutical Co., Ltd."Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
- (603896)"Zhejiang Shouxiangu Pharmaceutical Co., Ltd."Announcement on Conversion Results of "Shouxiangu 22 Convertible Bonds" and Share Changes
- Announcement on the 2026 Shareholder Rewards Event for the Mid-Autumn Festival
Later from Zhejiang Shouxiangu Pharmaceutical
- (603896)"Zhejiang Shouxiangu Pharmaceutical Co., Ltd."Announcement on Not Revising the Conversion Price of "Shou 22 Convertible Bonds" Downward
- (603896)"Zhejiang Shouxiangu Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
Follow Zhejiang Shouxiangu Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Shouxiangu Pharmaceutical